RTP Mobile Logo
Meet The Professor: Optimizing the Selection and Sequencing of Therapy for Patients with HER2-Positive Breast Cancer — Part 6 of a 6-Part Series (Webinar Audio Proceedings)
Released February 2022

Featuring perspectives from Dr Tiffany Traina. Published February 2, 2022. (Webinar Audio Proceedings)

CE Information and Faculty Disclosures

  • TARGET AUDIENCE
    This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of breast cancer.

    LEARNING OBJECTIVES

    • Appreciate the key clinical variables that affect the use of preoperative therapy and the selection of therapeutic regimens for patients with HER2-overexpressing localized breast cancer, and integrate this information into treatment decision-making.
    • Apply available research evidence to individualize the selection and use of adjuvant systemic therapy for patients with HER2-positive localized breast cancer who have received neoadjuvant treatment.
    • Evaluate published research data to guide the selection and duration of adjuvant or extended-adjuvant therapy for patients with HER2-overexpressing localized breast cancer.
    • Implement a long-term clinical plan for the management of advanced HER2-positive breast cancer, incorporating existing and recently approved targeted agents and regimens.
    • Design an optimal approach to the clinical care of patients with HER2-positive breast cancer and CNS metastases, considering the implications of prior therapeutic exposure, symptomatology and other factors.
    • Recognize common and rare side effects associated with approved and investigational anti-HER2 agents, and use this information to develop supportive management plans for patients undergoing treatment for HER2-positive breast cancer.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    CME credit is no longer available for this issue

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY
    Audio Program: This CME activity consists of an audio component.
    CME credit is no longer available for this issue

    Video Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Tiffany A Traina, MD
    Vice Chair, Oncology Care
    Section Head, Triple-Negative Breast Cancer Clinical Research Program
    Associate Attending Physician
    Breast Medicine Service
    Department of Medicine
    Memorial Sloan Kettering Cancer Center
    Associate Professor
    Weill Cornell Medical College
    New York, New York

    Consulting Agreements: Agendia Inc, AstraZeneca Pharmaceuticals LP, Athenex Inc, Ayala Pharmaceuticals, Blueprint Medicines, Daiichi Sankyo Inc, Eisai Inc, Ellipses Pharma, Exact Sciences Inc, Foundation Medicine, FUJIFILM Pharmaceuticals USA Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Ionis Pharmaceuticals Inc, iTeos Therapeutics, Merck, Pfizer Inc, Puma Biotechnology Inc, Seagen Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Ayala Pharmaceuticals, Carrick Therapeutics, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Immunomedics Inc, Innocrin Pharmaceuticals Inc, Novartis, Pfizer Inc.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AAbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc and Seagen Inc.

    Release date: February 2022
    Expiration date: February 2023

Acknowledge and close

Watch video
(WIFI is recommended for best performance):